Vivek Kundra Moves from the White House to Outcome Health

Vivek Kundra was the first CIO of the U.S. during the Obama administration and oversaw more than $80 billion in technology investments. Kundra moved on to Outcome Health, where he was appointed Chief Operating Officer after serving as Executive Vice President, Provider Solutions, a position he’s held since January 2017 when he joined Outcome.

“Vivek is an exceptional growth leader with a unique skillset that will allow him to drive large-scale technology transformation and revenue growth for the business,” says Rishi Shah, CEO of Outcome Health. “As we scale to 70% of all physician practices within our platform, Vivek’s leadership will deepen our commitment to customers at the core of our strategy and align operational investments during this rapid period of growth.”

Andrew Dunning Becomes San Francisco’s New Digitas Head

With more than 20 years experience spanning healthcare/pharmaceutical marketing and health information technologies, Andrew Dunning joins Digitas Health as Senior Vice President and General Manager of their San Francisco office. Digitas Health is the Agency of Now: The first health agency created for marketing and global connection.

“I am excited to join Digitas Health and have the opportunity to leverage my experience translating and communicating the value of both therapies and health IT innovations to healthcare providers and consumers,” Dunning states. “As the focus in healthcare continues to shift from volume to value, I believe the way healthcare companies connect with HCPs and patients has already changed. Clients will benefit by concentrating on the now, delivering their message during moments that matter in the doctor/patient relationships.”

AMAG Pharmaceuticals

Oscar Sanchez joins AMAG as Vice President of Quality. He is responsible for conceiving and implementing programs, policies, and procedures for quality assurance and control activities. His role spans across the company’s therapeutics, and multiple development stage products and cord blood banking services in addition to compliance oversight.


The R&D-driven global pharmaceutical giant announces two new area Vice Presidents of Sales, Primary Care, and Specialty. David Musselman will cover the East, where he most recently served as Director, Regional Accounts. At Astellas since 2007, Musselman has almost 20 years of pharma experience.

Lynn Gerber will lead the West, an area change from the East where she formerly held Musselman’s new position. Coming to Astellas in 2003 after a career at GSK, Gerber enters her new role with more than 25 years of pharma experience.

Discovery Worldwide

With 18 years of experience in the healthcare industry, Rico Ricketson will take the lead as the Head of Client Services at Discovery Worldwide. His focus will be on representing the voice of the customer while creating vital client brands.

G1 Therapeutics

A clinical-stage biopharmaceutical company dedicated to the discovery and development of cancer treatments appoints Sir Andrew Witty to their Board of Directors. Witty has been an advisor to governments globally, including the U.K., where he received knighthood in 2012 for services to the economy and their pharmaceutical industry.


Chairman of the Board of Directors, Bill Rastetter, has been appointed the Chief Executive Officer of GRAIL, Inc. He will continue the company’s mission to enable early cancer discovery to facilitate the development of cures.


As one of the biggest integrated communications firms, Makovsky, welcomes Rob Schachter as their new EVP, Deputy Head of Healthcare. Schachter comes to Makovsky from Lazar Partners where he held the role of Managing Director starting in 2015. He will report directly to Partner/Chief Strategy Officer, Susan Goldstein.


An AI leader in lab result application, the company added Lisa Kerber, Fernando Schwartz, PhD, and Stephen Silvestro to their team. As Chief Operating Officer, Kerber will use her background in healthcare informatics and consulting services to lead Prognos’ Life Sciences business line while overseeing their diagnostic partner alliances.

Silvestro, the new Chief Commercial Officer, will use his strategic sales experience to enhance customer commercialization within value-based patient relationships. As Chief Data Scientist, Dr. Schwartz will direct the data science advisory board, but will lead analysts, engineers, and scientists into the future of AI at Prognos.

Proteostasis Therapeutics, Inc.

A company that develops small molecule therapeutics for diseases appoints Helen M. Boudreau as Chief Financial Officer and Treasurer. Previously, she served on their Board of Directors, a position she had held since 2016.

Rx EDGE Pharmacy Networks

Three new Executive Directors of Sales join Rx EDGE Pharmacy Networks, including Joanne Carrara, Dennis Turner, and Chris Caggiano. Both Turner and Carrara come from positions at Accent Health as Senior Account Directors; Carrara oversaw the strategic development and direction of sales activities, while Turner maintained the overall market performance and revenue for their TV program.

Caggiano previously worked at Health Monitor Network, where he managed accounts and content development on a multi-platform level as Sales Manager.

RxC International

Philip Vorhies joins RxC International as Strategy Partner. His expertise spans many areas, including oncology, rare diseases, and specialty biopharma. He’ll lead the West Coast practice of this premier life sciences management consulting firm.

Rubius Therapeutics

The biotechnology company has expanded the role of David Epstein to Executive Chairman. He previously served as CEO of Novartis, where he was one of the first to identify the potential of CAR T-cell therapy.

Epstein joined Rubius as Chairman of the Board in early 2017. In June, Rubius successfully completed an oversubscribed private financing of $120 million, which will be used to advance the company’s RCT product portfolio.

SteadyMed Ltd.

SteadyMed Ltd. welcomes new VP of Medical Affairs, Jeff Myers, MD, PhD. He will continue the company’s focus on Trevyent, their lead drug candidate for treatment of Pulmonary Arterial Hypertension.


You May Also Like

How the Affordable Care Act Changes the Patient Journey (Part Three)

Non-Adherence, Technology and DTC A recent study from Capgemini Consulting found that the pharma ...

It’s Upgrade Time!

With the holiday shopping season right around the corner several companies are releasing the ...